ExplainerUpdated 7 min read
Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The short answer: of the three, only tesamorelin is a currently FDA approved drug with large randomized trials and a lawful prescription path. Sermorelin was approved decades ago for children, has only small human studies, and has no approved product today. Ipamorelin has never been approved and is not on the 503A bulks list. One small human pharmacology study showed a single IV infusion releases growth hormone in healthy men; its only randomized trial (postoperative ileus) was negative; no human trial measured body composition or muscle. [12] All three are prohibited in sport. [11]
People compare them because clinics sell all three for the same goals: fat loss, lean mass, recovery, and sleep. They are not interchangeable. This post puts them in one table, then explains each row and links the three pairwise comparisons. It does not give dosing advice.
Tesamorelin vs sermorelin vs ipamorelin at a glance
| Question | Tesamorelin | Sermorelin | Ipamorelin |
|---|---|---|---|
| How it works | Full 44 amino acid GHRH analog | 29 amino acid GHRH fragment | Ghrelin receptor agonist |
| FDA approval | Approved 2010; Egrifta WR current | Geref withdrawn 2009, not for safety | Never approved |
| Compounding | Not allowed (biologic since 2020) | Unlisted; depends on former approval | Not on 503A bulks list |
| Best human evidence | Phase 3 trials, 806 patients | 16 week trial, 19 older adults | One GH pharmacology study; one negative surgical trial |
| WADA | Prohibited | Prohibited | Prohibited |
Sources for the table, in row order: mechanism and approval [1] [4] [6] [7]; compounding [9] [10] [13]; human evidence [2] [5] [8] [12]; sport [11].
For head to head detail, see sermorelin vs tesamorelin, tesamorelin vs ipamorelin, and sermorelin vs ipamorelin.
How do tesamorelin, sermorelin, and ipamorelin work?
All three push the pituitary to release more of the body's own growth hormone, which raises IGF-1. They get there by two different receptors.
- Tesamorelin is a synthetic copy of the full 44 amino acid growth hormone releasing hormone with a hexenoyl group attached to one end. It binds the same receptor with similar potency to the natural hormone. [1]
- Sermorelin is the first 29 amino acids of the same hormone. [4] It works on the same receptor as tesamorelin but lacks tesamorelin's added hexenoyl group and the rest of the full sequence. [1]
- Ipamorelin is a five amino acid peptide that acts on the ghrelin receptor instead. In rats and pigs it released growth hormone about as potently as older secretagogues without raising cortisol or prolactin, which is the basis of its "selective" reputation. [7] That selectivity has not been confirmed in human trials.
Because GHRH analogs and ghrelin agonists act on different receptors, clinics often pair one of each. Pairing is a theory, not a tested treatment: no trial has tested tesamorelin with ipamorelin or sermorelin with ipamorelin. See the tesamorelin and ipamorelin blend page and the sermorelin and ipamorelin blend page.
Which one is FDA approved?
Tesamorelin. FDA first approved it in 2010. The current product, Egrifta WR, is indicated to reduce excess abdominal fat in adults with HIV who have lipodystrophy, and the label says it is not indicated for weight loss. [1]
Sermorelin, formerly. Sermorelin was approved as Geref as a diagnostic and later to treat growth hormone deficiency in children. The sponsor stopped selling it, the approvals were withdrawn, and in 2013 FDA determined in the Federal Register that Geref was not withdrawn for reasons of safety or effectiveness. [6] There is no approved sermorelin product on the market today.
Ipamorelin, never. Its only randomized human trial was a surgical study, and it has no approved use anywhere. [8] [10]
Can each one be prescribed and compounded legally?
This is where the three separate most sharply.
- Tesamorelin has a lawful prescription path, but only as Egrifta WR, which can be prescribed for the approved use or off-label. Tesamorelin is a biologic: Egrifta moved to a biologics license (BLA 022505) on March 23, 2020, and FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin has no lawful basis. [13] [14] Our tesamorelin prescription guide covers the process.
- Sermorelin sits in a gray zone. It is not on the 503A bulks list and was not placed on the Category 2 list of risky substances. [10] Many 503A pharmacies compound it on the basis of its former approval, and whether that satisfies the component of an approved drug condition depends on how state boards and pharmacies read the statute. [9]
- Ipamorelin is not approved and is not on the 503A bulks list. FDA placed it on the 503A Category 2 list in September 2023, the nominations were withdrawn in 2024, and it is now listed as a withdrawn nomination rather than on the bulks list. [10] Clinics still advertising compounded ipamorelin are operating outside FDA's stated categories.
The same readiness applies to the related GHRH analog CJC-1295, which also is not on the 503A bulks list. Compare it in tesamorelin vs CJC-1295 and read the combination evidence on the CJC-1295 and ipamorelin blend page. State rules are collected on our legality hub.
Which has the best human evidence?
Tesamorelin, by a wide margin. Two double-blind phase 3 trials randomized 806 adults with HIV and excess abdominal fat. At 26 weeks, visceral fat fell by 15.4% relative to placebo, triglycerides fell, and glucose did not meaningfully change. [2] A later 12 month randomized trial in 61 people with HIV and fatty liver cut liver fat by an absolute 4.1 percentage points. [3] The full results timeline is in tesamorelin before and after.
Sermorelin, modest and old. The pediatric program that supported Geref showed faster growth in children with growth hormone deficiency. [4] In adults, the key study gave 19 people aged 55 to 71 a sermorelin analog nightly for 16 weeks. Growth hormone and IGF-1 rose and skin thickened in both sexes, while lean body mass and insulin sensitivity improved in men only; weight, bone density, and sleep quality did not change. [5] No trial has tested sermorelin for fat loss or performance in adults.
Ipamorelin, none for its marketed uses. The only randomized human trial, a double-blind, placebo-controlled study, gave intravenous ipamorelin after bowel surgery to 117 adults and found no significant difference from placebo in time to first tolerated meal. [8] That trial is why our record grades ipamorelin as human RCT evidence; the grade describes how the evidence was gathered, not whether ipamorelin works for what it is sold for. No published trial measured growth hormone, IGF-1, muscle, or fat with the injected doses sold today. Its human growth hormone data come from one study of a single intravenous infusion in 40 healthy men, and the rest come from animals. [7] [12]
None of the three has a trial showing muscle growth. We cover that question in does tesamorelin build muscle and rank the whole field in peptides for muscle growth.
Which one is right for a given goal?
We do not recommend a product, but the evidence points in clear directions.
- Excess abdominal fat with HIV: tesamorelin is the approved treatment. Start with the HIV lipodystrophy page.
- Diagnosed growth hormone deficiency: diagnosis and treatment belong with an endocrinologist, and none of these three is an approved adult treatment. [1] [6] The growth hormone deficiency page lists the standard of care and grades each option.
- General fat loss, lean mass, or anti-aging: no trial supports any of the three in healthy adults. The fat loss and body composition page lists what does have human evidence.
- Tested athletes: none. All three are on the WADA list. [11]
What do they cost?
Branded Egrifta WR costs thousands of dollars a month at cash prices, and compounded tesamorelin has no lawful price because tesamorelin is a biologic. Compounded sermorelin is priced far lower. Ipamorelin has no lawful price because it is neither approved nor on the 503A bulks list. See the tesamorelin cost page and the sermorelin cost page for dated prices by channel. Status changes are logged on the tesamorelin, sermorelin, and ipamorelin regulatory trackers, and the general route to a lawful prescription is in how to get peptides prescribed. For what clinics mean by the label, see what is peptide therapy.
What's actually offered, and what that means for you
Tesamorelin
Compounded tesamorelin is widely offered by clinics and telehealth prescribers. Tesamorelin is FDA approved, but FDA deemed its application (022505) a biologics license in March 2020, and biologics cannot be compounded under 503A or 503B. Compounded versions have no lawful basis. [1] [13] [14]
- A pharmacy that compounds tesamorelin is taking a regulatory risk: biologics cannot be compounded under 503A or 503B. [13] [14]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]
If you're going ahead anyway. Each step is on the tesamorelin page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded version lawful or safe; only the approved product is lawful. [13]
Sermorelin
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [15] [16] [17]
- A pharmacy that compounds sermorelin relies on FDA's interim policy, which has conditions and which FDA can change, so it carries some regulatory risk. [18]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]
If you're going ahead anyway. Each step is on the sermorelin page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [14]
Ipamorelin
Many clinics offer ipamorelin anyway. FDA has also found compounding pharmacies and an online seller offering it. [16] [19] [20] [21]
- A pharmacy that compounds ipamorelin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [15] [22]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]
If you're going ahead anyway. Each step is on the ipamorelin page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound ipamorelin, with or without a prescription. [10]
State boards
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [23]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [24] [25]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Pages referenced in this article
- PeptideTesamorelin
- PeptideSermorelin
- PeptideIpamorelin
- ComparisonSermorelin vs tesamorelin
- ComparisonTesamorelin vs ipamorelin
- ComparisonSermorelin vs ipamorelin
- CostEgrifta WR (tesamorelin) cost
- CostSermorelin cost
- RegulatoryTesamorelin regulatory timeline
- RegulatorySermorelin regulatory timeline
- RegulatoryIpamorelin regulatory timeline
- ConditionGrowth hormone deficiency and GH secretagogue use
- ConditionHIV associated lipodystrophy
- Page/blends/tesamorelin-ipamorelin
- Page/blends/sermorelin-ipamorelin
- IndexState legal guides
Frequently asked questions
What is the difference between tesamorelin, sermorelin, and ipamorelin?
Tesamorelin and sermorelin both act on the growth hormone releasing hormone receptor; tesamorelin is the full 44 amino acid sequence with an added hexenoyl group, while sermorelin is a 29 amino acid fragment. Ipamorelin acts on a different receptor, the ghrelin receptor. [1] [4] [7]
Which one is FDA approved?
Only tesamorelin, as Egrifta WR, for excess abdominal fat in adults with HIV lipodystrophy. Sermorelin was approved as Geref, but those approvals were withdrawn in 2009 for reasons FDA later said were not safety or effectiveness. Ipamorelin has never been approved. [1] [6]
Which has the best human evidence?
Tesamorelin, with two phase 3 trials of 806 patients pooled. Sermorelin has small, older trials, including a 19 person adult study. Ipamorelin's only randomized human trial tested bowel recovery after surgery and was negative. [2] [5] [8]
Can all three be compounded legally?
No. Tesamorelin became a biologic in 2020, and biologics are not eligible for 503A compounding, so the only lawful product is Egrifta WR by prescription. Ipamorelin was placed on FDA's Category 2 list in 2023 and is now a withdrawn 503A nomination that is not on the bulks list. Sermorelin's position depends on how state boards read its former approval. [10] [13] [14]
Are they banned in sport?
Yes, all three. WADA section S2 lists growth hormone releasing hormone analogues, including tesamorelin and sermorelin, and growth hormone secretagogues, including ipamorelin, as prohibited at all times. [11]
Sources
Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.
- [1]FDA prescribing information for Egrifta WR (tesamorelin) for injection, revised March 2025, via DailyMed (Indications, Description, and Clinical Studies sections)FDA, 2025
- [2]Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010PubMed 20554713, 2010
- [3]Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019PubMed 31611038, 2019
- [4]Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999PubMed 18031173, 1999
- [5]Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997PubMed 9141536, 1997
- [6]Federal Register, March 4, 2013: Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (NDA 19-863 and NDA 20-443)Federal Register, 2013
- [7]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
- [8]Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
- [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic Act (compounding for an identified individual patient; components of approved drugs)FDA
- [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA, 2026